Abeona Therapeutics Inc. Common Stock
Here’s whether Abeona Therapeutics Inc. Common Stock (ABEO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.23% over 10 days); RSI 48 — healthy momentum range; 3-month momentum positive (+9.0%); rising volume confirms the move (1.35x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative); weak 1-year return of -17.2%. Currently 21.8% off its 52-week high. Score: +4/7.
ABEO is holding above its long-term 200-day MA ($5.39) but has slipped below the 50-day MA ($6.30), pointing to short-term weakness in an otherwise intact trend. An RSI of 47.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -17.2% compares to +20.4% for SPY (trailed the market by 37.6%). The current 21.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.